Thursday, August 9, 2012
Publication and contact
Assays & screens
Impact of receptor tyrosine kinase (RTK) ligands on sensitivity
of human tumor-derived cell lines to kinase inhibitors
Analysis of the impact of
RTK ligands on sensitivity of human tumor-derived cell lines to kinase inhibitors
could guide combination therapy to prevent drug resistance. In about half of BRAF mutant melanoma cell lines, the RTK ligand hepatocyte growth factor/scatter factor
(HGF/SF) induced c-Met proto-oncogene (MET;
HGFR) expression and
resistance to the BRAF inhibitor Zelboraf vemurafenib. In
these cell lines, co-treatment with the MET kinase inhibitorXalkori crizotinib
prevented resistance to Zelboraf. In patients with BRAF mutant melanoma, increased plasma HGF/SF levels
correlated with poorer survival outcomes than normal HGF/SF levels. Next
steps include analyzing the effects of RTK ligands on larger numbers of
kinase-activated, human tumor-derived cell lines.
Zelboraf, from Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd.
and Roche, is marketed to treat
melanoma, in Phase I testing for colorectal cancer and in Phase II testing
for thyroid cancer.
Xalkori from Pfizer Inc., which also
inhibits anaplastic lymphoma kinase
(ALK), is marketed to treat
non-small cell lung cancer (NSCLC) and is in Phase I testing to treat solid
SciBX 5(31); doi:10.1038/scibx.2012.825
Published online Aug. 9, 2012
Patent and licensing status
Wilson, T.R. et al. Nature; published online July 4, 2012;
Contact: Jeffrey Settleman, Genentech Inc., South San
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]